Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.
about
Statins and fibrates for preventing melanomaIsolated limb perfusion for malignant melanoma: systematic review on effectiveness and safetyTreatment of metastatic melanoma: an overviewHuman periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cellsQuantitative magnetic resonance and optical imaging biomarkers of melanoma metastatic potentialFibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trialCirculating serologic and molecular biomarkers in malignant melanomaOverview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanomaNRAS mutation status is an independent prognostic factor in metastatic melanoma.Developments in Intralesional Therapy for Metastatic MelanomaBurden of illness for metastatic melanoma in Canada, 2011-2013Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A ReviewClonal expansions of 6-thioguanine resistant T lymphocytes in the blood and tumor of melanoma patientsGene Expression Profiling of Primary Cutaneous Melanoma and Clinical OutcomeFinal version of 2009 AJCC melanoma staging and classificationClinical and biological determinants of melanoma progression: Should all be considered for clinical management?Short length of stay and rapid recovery to normal function after surgery for metastatic melanoma to abdominal and retroperitoneal viscera.Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1RRandomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccineTumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses.Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR).Melanoma in buckinghamshire: data from the inception of the skin cancer multidisciplinary team.The gene expression signatures of melanoma progressionTreatment options for limited or symptomatic metastatic melanoma.Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma.Prognostic significance of vascularity in cutaneous melanoma: pilot study using in vivo confocal scanning laser microscopy.B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.Prevalence and patterns of soft tissue metastasis: detection with true whole-body F-18 FDG PET/CT.Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases.A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanomaOblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.Results of systemic treatment of cutaneous melanoma in inoperable stage III and IVMalignant melanoma (non-metastatic).Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma.Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter studyProteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
P2860
Q24245521-BA8F65EE-7EF3-4EC5-993A-B5D8B08860FFQ24633360-C4869FF8-F65E-456D-9A52-9EE284703FC3Q24642384-52E067FD-159E-40AB-AC60-B5FBA3C75281Q24642524-61873232-D242-4C80-97E0-E0276EFBC9E9Q24655570-66FDB9A6-5E07-47E9-9247-34E9822FE425Q24807379-78BB7E41-1AC6-487D-A99A-7FE98C60FFB7Q27020946-6475AB64-CEB1-44A7-8519-823BC7723F73Q27027762-71CD4F54-53D4-4832-A415-27A94B8CB7B6Q27851695-B64705D2-7BA5-4171-B318-1B248855C762Q28069615-F240DDAF-B935-4611-A788-4A08421BACD9Q28354125-20EE4D9B-E988-4D02-BBBF-8B961C312FBEQ28394719-98A2BF75-0BEB-4879-9BA9-96BD56A417E3Q28742878-09183C0E-35EF-4BC8-AD59-118472A1A67FQ29011337-DB84E0C5-19FE-49CD-B0A1-E4E9891744AEQ29614803-D8717366-F49A-49BC-94F8-0A18171B3ABAQ30252150-47708DEA-EE38-4F44-90DE-C2A0A4EE3747Q30356693-1DB590CF-2142-4913-991A-7BF2ADB35DE4Q30384793-B841A731-6C79-481A-A999-E8FCE88F1B49Q30425784-06AB0208-3F95-4E4E-AA4E-EE9B721EEDC0Q30425914-57C4574D-C654-45B9-A8F3-CA409E1F6B4FQ30541916-772BB501-3D53-45CF-A69A-C2EA9434D806Q30669529-752833D2-A840-4BFD-9537-3017F547B5A5Q30684853-E8C6BE8E-5A96-4EBB-8E98-9CEA8F1C3ED7Q30850724-C04EE3B5-80F8-4442-9732-B6D74E947DADQ31161199-F008A169-CEE2-4623-BFC9-4CA447AFCCD1Q33234917-A6836C0B-DC5F-4BF6-88A2-8C0D032F18EAQ33263686-3FD12B23-7A66-49BD-9574-E8444A167490Q33269966-8D32F195-E0DE-4C13-B349-1B0886A11B35Q33274670-DDD76AA4-8E14-40AA-931C-AA8E916F4155Q33310094-E01E16F0-A341-4B9D-A004-C0062057CF21Q33345263-BC98ACE7-4D6F-4EDA-B429-E1E43929123EQ33373492-9A30A442-8B19-4C9D-98FD-D609A8F6EDA0Q33403800-8341481F-4348-4A4D-8753-1A92B996C87AQ33408564-DE1D2E50-7E88-4017-BC7F-E5DBAA4B4F42Q33448157-A949E9B6-05BC-47A1-9C87-F032CF4F324EQ33488712-E029B0EE-C5EF-4CA4-A6E3-EC54783D6DD1Q33492805-D4A1711C-173A-4CFE-A205-D883A04F3AE1Q33557480-DAC5FAA6-1464-4B3E-B50C-E6C80338B1F2Q33567330-BD04BA39-6CE4-4724-91B6-F56521926484Q33613608-6B62E4D6-37D8-4144-943F-7DD7B6C96890
P2860
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Final version of the American ...... system for cutaneous melanoma.
@ast
Final version of the American ...... system for cutaneous melanoma.
@en
Final version of the American ...... system for cutaneous melanoma.
@nl
type
label
Final version of the American ...... system for cutaneous melanoma.
@ast
Final version of the American ...... system for cutaneous melanoma.
@en
Final version of the American ...... system for cutaneous melanoma.
@nl
prefLabel
Final version of the American ...... system for cutaneous melanoma.
@ast
Final version of the American ...... system for cutaneous melanoma.
@en
Final version of the American ...... system for cutaneous melanoma.
@nl
P2093
P1476
Final version of the American ...... system for cutaneous melanoma.
@en
P2093
A C Buzaid
A Houghton
D L Morton
D S Reintgen
I D Fleming
J A Thompson
J E Gershenwald
P304
P356
10.1200/JCO.2001.19.16.3635
P407
P577
2001-08-01T00:00:00Z